Elmer, New Jersey (PRWEB) December 23, 2011
Dr. Ingrid Warmuth is one of the selected providers for the early release of Xeomin. The Food and Drug Administration (FDA) recently approved this new botulinum toxin type A in July, 2011 for aesthetic indication; particularly to treat moderate to severe frown lines, or "11's" between the eyebrows.
Xeomin was initially approved by the FDA for use in adults with cervical dystonia and blepharospasm. Cervical dystonia is marked by abnormal neck pain and movements while blepharospasm is characterized by abnormal, involuntary blinking or spasm of the eyelids.
Since its FDA approval for aesthetic indication, Xeomin (incobotulinumtoxinA) is the newest contender in a growing list of botulinum toxin type A injectables.
In addition to providing new injectables, such as Xeomin, Dr. Warmuth Skin Care Center specializes in many areas of dermatology. These areas include medical dermatology, pediatric dermatology, MOHS micrographic surgery, accent laser treatment, fractional laser skin resurfacing, nail disorders, psoriasis management, skin cancer treatment, hair disorders and many skin rejuvenation procedures.
Dr. Warmuth Skin Care Center is located at 420 Front Streeet, Elmer, New Jersey. Call (856) 358-1500 to schedule your appointment.
Xeomin is manufactured by Merz Pharmaceuticals, and has been used by more than 84,000 people worldwide. It is now approved for use in 20 countries.